(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual revenue growth rate of 6.68% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Jazz Pharmaceuticals's revenue in 2026 is $4,438,645,000.On average, 22 Wall Street analysts forecast JAZZ's revenue for 2026 to be $288,428,743,540, with the lowest JAZZ revenue forecast at $270,358,811,380, and the highest JAZZ revenue forecast at $302,232,163,940. On average, 22 Wall Street analysts forecast JAZZ's revenue for 2027 to be $309,824,045,160, with the lowest JAZZ revenue forecast at $279,519,263,100, and the highest JAZZ revenue forecast at $330,529,175,760.
In 2028, JAZZ is forecast to generate $339,501,399,020 in revenue, with the lowest revenue forecast at $294,953,996,820 and the highest revenue forecast at $400,236,448,780.